BioShares Biotechnology Net Asset

BioShares Biotechnology Clinical Trials -- USA Etf  

USD 32.56  1.3  4.16%

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Net Asset Analysis

Net Asset is current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assest is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
BioShares Biotechnology 
Net Asset 
Current Market Value 
Current Liabilities 
31.18 M

About Net Asset

Net Asset is the value used in calulating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formullay that uses closing prices of all positions in the fund's portfolio.
Compare to competition
Based on recorded statements BioShares Biotechnology Clinical Trials has Net Asset of 31.18 M. This is 33.08% higher than that of the Bio Shares family, and 33.08% higher than that of Health category, The Net Asset for all etfs is 96.49% higher than the company.

Peer Comparison

BioShares Biotechnology Net Asset Comparison
  Net Asset 
      BioShares Biotechnology Comparables 
BioShares Biotechnology is currently under evaluation in net asset as compared to similar ETFs.

Did you try this?

Run Technical Analysis Now

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
Hide  View All  NextLaunch Technical Analysis

Asset Allocation

Fund Instrument Allocation for BioShares Biotechnology
The fund invests 100.0% of asset under management in tradable equity instruments, with the rest of investments concentrated in .
      Instrument Type 

Fundamental Indicators

Current BioShares Biotechnology financial ratios